Intraocular Bevacizumab (Avastin) for Rubeosis Iridis

Sponsor
Instituto de Olhos de Goiania
Study ID
NCT00557232
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers. Bevacizumab may have a role in treating ocular disorders involving fibrovascular proliferation. To determine whether intraocular bevacizumab decreases rubeosis iridis in patients with neovascular glaucoma.

Key Dates

First listed
Nov 12, 2007
Start date
Nov 30, 2006
Status verified
Nov 2011
Primary completion
Oct 31, 2011
Completion
Nov 30, 2011

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Intraocular Bevacizumab (Avastin) for Rubeosis Iridis [ Time Frame: Compare results ]

Related Studies